Bioline RX Ltd Sponsored ADR (BLRX) is scheduled to report 3rd quarter earnings on 11/15/2023.
Regarding Q3 estimates, Wall Street analysts expect Bioline RX Ltd Sponsored ADR to post earnings of -$0.21 per share. Last quarter, Bioline RX Ltd Sponsored ADR missed earnings estimates, reporting EPS of -$0.30 on estimates of -$0.17. The stock rose by 4.51% the day after the last earnings release.
Year-to-date, BLRX stock has risen by 120.00%.
About Bioline RX Ltd Sponsored ADR
BioLineRx Ltd. is a clinical-stage biopharmaceutical company, which includes indentifying, in-licensing, and developing therapeutic candidates. Its in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, and develops them through pre-clinical and clinical stages, and then partners with pharmaceutical companies clinical development and commercialization. The company was founded in April 2003 and is headquartered in Modi’in, Israel.
Stay up-to-date on earnings this week, with TipRanks’ Earnings Calendar.
